Mortalin contributes to colorectal cancer by promoting proliferation and epithelial–mesenchymal transition

This study focused on the expression of mortalin in colorectal cancer (CRC). Mortalin activated the Wnt/β‐catenin pathway to accelerate cell proliferation and the epithelial–mesenchymal transition (EMT) program. Data from online databases displayed that the expression of mortalin was high in CRC, wh...

Full description

Saved in:
Bibliographic Details
Published in:IUBMB life 2020-04, Vol.72 (4), p.771-781
Main Authors: Xu, Ming, Zhang, Yuan, Cui, Minghua, Wang, Xinyue, Lin, Zhenhua
Format: Article
Language:English
Subjects:
Catenin
Cell growth
Cell proliferation
Colorectal cancer
Colorectal carcinoma
epithelial–mesenchymal transition
Immunofluorescence
Medical prognosis
Mesenchyme
mortalin
proliferation
survival analysis
Therapeutic applications
Wnt protein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study focused on the expression of mortalin in colorectal cancer (CRC). Mortalin activated the Wnt/β‐catenin pathway to accelerate cell proliferation and the epithelial–mesenchymal transition (EMT) program. Data from online databases displayed that the expression of mortalin was high in CRC, which was further validated using clinical specimens. Meanwhile, high mortalin expression was positively associated with a poor overall survival rate. Suppression of mortalin inhibited CRC cell proliferation as evaluated by the 3‐(4,5‐dimethyl‐2‐thiazolyl)‐2,5‐diphenyl‐2‐H‐tetrazolium bromide (MTT), colony formation, and immunofluorescence staining assays. In addition, depletion of mortalin inhibited CRC cell EMT progression and deactivated the Wnt/β‐catenin pathway. Altogether, mortalin is highly expressed in CRC and may indicate a poor prognosis. Mortalin accelerated CRC progression by stimulating cell proliferation and the EMT program. This study may provide a potential clinical therapeutic target for CRC.
ISSN:1521-6543
1521-6551
DOI:10.1002/iub.2176